

***Complete Listing of the Claims***

This listing of claims will replace all prior versions, and listings of claims in the application.

1 - 34. (Canceled)

35. (New)     A method for the treatment or prevention of neuroectodermal tumors, malignant astrocytomas, or glioblastomas, said method comprising administering to an animal in need thereof an antisense oligonucleotide which is complementary to an NTP mRNA sequence corresponding to nucleotides 150-1139 of SEQ ID NO:1.

36. (New)     The method of claim 35, wherein said method is a method of treating neuroectodermal tumors, malignant astrocytomas, or glioblastomas.

37. (New)     The method of claim 35, wherein said antisense oligonucleotide is a 15 to 40 mer.

38. (New)     The method of claim 35, wherein said antisense oligonucleotide is selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11.

39. (New)     The method of claim 35, wherein said antisense oligonucleotide is deoxyribonucleic acid.

40. (New) The method of claim 35, wherein said antisense oligonucleotide is a deoxyribonucleic acid phosphorothioate.

41. (New) The method of claim 35, wherein said antisense oligonucleotide is a derivative of a deoxyribonucleic acid or a derivative of a deoxyribonucleic acid phosphorothioate.

42. (New) The method of claim 35, wherein said antisense oligonucleotide is administered to said animal as part of a pharmaceutically acceptable carrier.

43. (New) A method for the treatment or prevention of neuroectodermal tumors, malignant astrocytomas, or glioblastomas, said method comprising administering to an animal in need thereof a ribozyme comprising a target sequence which is complementary to an NTP mRNA sequence corresponding to nucleotides 150-1139 of SEQ ID NO:1.

44. (New) The method of claim 43, wherein said method is a method of treating neuroectodermal tumors, malignant astrocytomas, or glioblastomas.

45. (New) The method of claim 43, wherein said ribozyme is administered to said animal as part of a pharmaceutically acceptable carrier.

46. (New) A method for the treatment or prevention of neuroectodermal tumors, malignant astrocytomas, or glioblastomas, said method comprising administering to an

animal in need thereof an oligonucleotide that forms one or more triple-stranded regions with the coding region of AD7c-NTP DNA, wherein said oligonucleotide has the sequence 3'X5'-L-5'X3' or 5'X3'-L-3'X5', wherein X comprises a nucleotide sequence corresponding to nucleotides 150-1139 of SEQ ID NO:1, and wherein L represents an oligonucleotide linker or a bond.

47. (New) The method of claim 46, wherein said method is a method of treating neuroectodermal tumors, malignant astrocytomas, or glioblastomas.

48. (New) The method of claim 46, wherein said oligonucleotide is administered to said animal as part of a pharmaceutically acceptable carrier.

49. (New) A method for the treatment or prevention of neuroectodermal tumors, malignant astrocytomas, or glioblastomas, said method comprising administering to an animal in need thereof a ribonucleotide external guide nucleic acid molecule comprising a 10-mer nucleotide sequence corresponding to nucleotides 150-1139 of SEQ ID NO:1 fused to a 3'NCCA nucleotide sequence, wherein N is a purine.

50. (New) The method of claim 49, wherein said method is a method of treating neuroectodermal tumors, malignant astrocytomas, or glioblastomas.

51. (New) The method of claim 49, wherein said ribonucleotide external guide nucleic acid molecule is selected from the group consisting of SEQ ID NO:12, SEQ ID NO:13 and SEQ ID NO:14.

52. (New) The method of claim 49, wherein said ribonucleotide external guide nucleic acid molecule is administered to said animal as part of a pharmaceutically acceptable carrier.